Abstract
Altered mean platelet volume (MPV) is found in several malignancies. Remarkably, there is little consensus on using the value of MPV in the prognostic evaluations of renal cell carcinoma (RCC). The aim of this study is to examine the feasibility of MPV value as a prognostic indicator of RCC. The retrospective study recruited 306 consecutive RCC patients between January 2009 and December 2009. The relationships between MPV and clinicopathological characteristics were analyzed. Kaplan-Meier method and Cox regression were used to evaluate the prognostic impact of MPV. Of the 306 RCC patients, low MPV levels were detected in 61 (19.9%) patients. Reduced MPV was associated with histology types, T classification, UCLA Integrated Scoring System (UISS) category, and Mayo clinic stage, size, grade, and necrosis score (SSIGN) category (P < 0.05). Patients with decreased MPV had significantly shorter survival time than patients with normal MPV (P < 0.001). Cox regression analysis revealed that reduced MPV was an independent prognostic factor for overall survival (hazard ratio, 1.758; 95% confidence interval [CI], 1.083–2.855, P = 0.023). Moreover, the prognostic accuracy of TNM stage, UISS, and SSIGN prognostic models were improved when MPV was added. In conclusion, reduced MPV is identified as an independent predictor of adverse clinical outcome in RCC.
Highlights
Renal cell carcinoma (RCC) is the most common type of malignant tumor in the adult kidney and represents 2–3% of all adult cancers[1]
This study found that Mean platelet volume (MPV) correlates with patient’s survival and is an independent predictor of adverse clinical outcome in renal cell carcinoma (RCC)
Platelets act as a crucial modulator in tumor development, tumor cell growth, angiogenesis, and metastasis
Summary
Renal cell carcinoma (RCC) is the most common type of malignant tumor in the adult kidney and represents 2–3% of all adult cancers[1]. Searching for biomarkers to predict the prognosis in RCC is of critical importance. Platelets are critical for cancer progression and metastasis[2]. Elevated platelets are associated with a reduction in overall survival and poorer prognosis in various types of cancer, such as pancreatic, gastric, colorectal, endometrial, and ovarian cancers[4,5,6,7,8]. A normal platelet count could conceal the presence of highly hypercoagulative and pro-inflammatory cancer phenotypes in the presence of efficient compensatory mechanisms[9]. The purpose of this study was to assess whether MPV holds a prognostic role in RCC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
